2020 Was the Turning Point for CRISPR
By Emily Mullin,
Future Human
| 12. 13. 2020
Amid a raging global pandemic, the field of gene editing made major strides in 2020. For years, scientists have been breathlessly hopeful about the potential of the gene-editing tool CRISPR to transform medicine. In 2020, some of CRISPR’s first real achievements finally came to light — and two of CRISPR’s inventors won the Nobel Prize.
The idea behind CRISPR-based medicine sounds simple: By tweaking a disease-causing gene, a disease could be treated at its source — and possibly even cured. The other allure of gene editing for medical reasons is its permanence. Instead of a lifetime of drugs, patients with rare and chronic diseases like muscular dystrophy or cystic fibrosis could instead get a one-time treatment that could have benefits for life.
This idea has proven difficult to realize. For one, scientists have to figure out how to get the gene-editing molecules to the right cells in the body. Once there, the molecules need to modify enough cells in order to have an impact on the disease. Both of these things need to happen without causing unpleasant or toxic side...
Related Articles
By Marisa Flook , BioNews | 06.29.2026
An anti-ageing gene therapy not approved by the US Food and Drug Administration (FDA) is set to be offered by an American company at overseas clinics outside of US jurisdiction.
The treatment, developed by Minicircle from Austin, Texas, uses a...
By Philip Ball , Nature | 06.17.2026
Our genomes are full of mutations that have the potential to damage our health or even kill us. Yet most of them rarely cause problems. Why? It’s partly thanks to a family of proteins that mask, or ‘buffer’, the ill...
By Philip Ball, Quanta Magazine | 06.18.2026
Since its molecular structure was deduced in the 1950s, DNA has been hailed by many biologists as the secret of life. They’ve read and studied the information stored in the DNA found in the cells of living organisms, known as...
By Arche Noah, GMWatch | 06.17.2026
The European Parliament has voted for a wide-reaching deregulation of New Genomic Techniques (NGTs). There was no majority for amendments stopping patents on conventionally classically bred plants or NGT plants. “Today’s vote is a missed opportunity to protect Europe’s farmers...